Publication:
Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study

dc.contributor.authorDominguez-Molina, Beatriz
dc.contributor.authorTarancon-Diez, Laura
dc.contributor.authorMilanés-Guisado, Yusnelkis
dc.contributor.authorGenebat, Miguel
dc.contributor.authorResino, Salvador
dc.contributor.authorRodriguez, Carmen
dc.contributor.authorGonzález-García, Juan
dc.contributor.authorRallón, Norma
dc.contributor.authorPernas, Maria
dc.contributor.authorCasado, Concepcion
dc.contributor.authorLopez-Galindez, Luis Cecilio
dc.contributor.authorLeón, Agathe
dc.contributor.authorBenito, José Miguel
dc.contributor.authorGarcía, Felipe
dc.contributor.authorDel Romero, Jorge
dc.contributor.authorViciana, Pompeyo
dc.contributor.authorLopez-Cortes, Luis F
dc.contributor.authorLeal, Manuel
dc.contributor.authorRuiz-Mateos, Ezequiel
dc.contributor.authorECRIS integrated in the Spanish AIDS Research Network
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España)
dc.contributor.funderRegional Government of Andalusia (España)
dc.contributor.funderMinisterio de Educación (España)
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderRETICS-Sida (RIS-ISCIII) (España)
dc.date.accessioned2020-09-29T09:08:49Z
dc.date.available2020-09-29T09:08:49Z
dc.date.issued2020-09
dc.description.abstractIntroduction: HIV-controllers have the ability to spontaneously maintain viraemia at low or undetectable levels in the absence of antiretroviral treatment. Furthermore, HIV-controllers seem to have a superior capacity to spontaneously clear hepatitis C virus (HCV) compared to non HIV-controllers. Some of these subjects eventually lose HIV-controller status (transient controllers), whereas some HIV-controllers show a persistent natural HIV control (persistent controllers). We aimed to analyse whether persistent controllers have superior capacity to spontaneously clear HCV compared to transient controllers. Methods: We recruited HIV-controllers from January 1981 up to October 2016 with available antibodies to HCV (anti-HCV) data (n = 744). Factors associated with HIV spontaneous control in relation to HCV status were analysed in persistent and transient HIV-controllers with anti-HCV positive (n = 202 and n = 138 respectively) in comparison with 1700 HCV positive non HIV-controllers recruited from January 1981 up to March 2018, bivariate and multivariate analyses, following a logistic regression model, were applied. In addition, the factors related to the loss and time to lose HIV-controller status were explored (n = 744) using Log rank test and Kaplan-Meier curves, in this case the multivariate analysis consisted in a Cox regression model. Results: A higher frequency of HCV spontaneous clearance was found in persistent HIV-controllers (25.5%) compared to non-controllers (10.2%). After adjusting for potential confounders, as sex, age, HIV transmission risk, CD4+ T-cell nadir and time of follow-up, HCV clearance was independently associated with persistent HIV spontaneous control (p = 0.002; OR (95% CI) = 2.573 (1.428 to 4.633)), but not with transient spontaneous control (p = 0.119; 1.589 (0.888 to 2.845)). Furthermore, persistent HIV-controllers were more likely to spontaneously clear the HCV in comparison with transient controllers (p = 0.027; 0.377 (0.159 to 0.893). Finally, not to lose or lengthen the time of losing this control was independently associated with HCV spontaneous clearance (p = 0.010; 0.503 (0.297 to 0.850). Conclusions: This study shows an association between spontaneous persistent HIV-control and HCV spontaneous clearance. The study findings support the idea of preserved immune mechanisms in persistent HIV control implicated in HCV spontaneous clearance. These results highlight persistent HIV-controllers but not transient controllers as a good model of functional HIV cure.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by the Instituto de Salud Carlos III (research contracts CPII014/00025 to E.R.‐M., and FI14/00431 to L.T.‐D. and research projects PI12/02283, PI16/00684, PI19/01127 to E.R.‐M.) and Red Temática de Investigación Cooperativa en SIDA (Projects RD12/0017/0029, RD12/0017/0031, and RD16/0025/0020 and RD16/0025/0013), which is included in the Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2008 to 2011 and 2013 to 2016, Instituto de Salud Carlos III, Fondos FEDER. E.R.‐M. was supported by Consejería de Salud y Bienestar Social of Junta de Andalucía through the Nicolás Monardes program (C‐0032/17), N Rallón is a Miguel Servet investigator from the Spanish Carlos III Institute of Health (ISCIII), grant CP14/00198, Madrid, Spain and B.D.M. received a grant from The Spanish Ministry of Education (FPU13/02451). Work in CL‐G’s laboratory was supported by grants SAF (2010 to 17226) and (2016‐77894‐R) from MINECO (Spain) and FIS (PI 13/02269, ISCIII) and in part by the RIS‐RETIC grants RD06/006/0036 and RD12/0017/0028 funded by the ISC III‐FEDER. MP has a contract of RIS‐RETIC RD12/0017/0036.es_ES
dc.format.number9es_ES
dc.format.pagee25607es_ES
dc.format.volume23es_ES
dc.identifier.citationJ Int AIDS Soc. 2020 Sep;23(9):e25607.es_ES
dc.identifier.doi10.1002/jia2.25607es_ES
dc.identifier.e-issn1758-2652es_ES
dc.identifier.journalJournal of the International AIDS Societyes_ES
dc.identifier.pubmedID32909370es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11081
dc.language.isoenges_ES
dc.publisherWiley
dc.relation.projectFECYTinfo:eu_repo/grantAgreement/ES/RD12/0017/0029
dc.relation.projectFECYTinfo:eu_repo/grantAgreement/ES/RD12/0017/0031
dc.relation.projectFECYTinfo:eu_repo/grantAgreement/ES/RD16/0025/0020
dc.relation.projectFECYTinfo:eu_repo/grantAgreement/ES/RD16/0025/0013
dc.relation.projectFECYTinfo:eu_repo/grantAgreement/ES/FPU13/02451
dc.relation.projectFECYTinfo:eu_repo/grantAgreement/ES/SAF2016‐77894‐R
dc.relation.projectFECYTinfo:eu_repo/grantAgreement/ES/SAF2010‐17226
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/CPII014/00025
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/FI14/00431
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/PI12/02283
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/PI16/00684
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/PI19/01127
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/PI13/02269
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/CP14/00198
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/RD06/006/0036
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/RD12/0017/0028
dc.relation.projectFISinfo:eu_repo/grantAgreement/ES/RD12/0017/0036
dc.relation.publisherversionhttps://doi.org/10.1002/jia2.25607es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHIVes_ES
dc.subjectHCVes_ES
dc.subjectHIV-controllerses_ES
dc.subjectPersistentes_ES
dc.subjectTransientes_ES
dc.subjectHCV spontaneous clearancees_ES
dc.titlePersistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort studyen
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublicationcca7e901-0913-4b71-8c9d-ee7dd20b6458
relation.isAuthorOfPublication7e48a263-54c3-4de0-81e7-f7446c918f2d
relation.isAuthorOfPublicationf57c2687-907b-44ea-a780-7920ff8b9b41
relation.isAuthorOfPublication.latestForDiscovery89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationa16348d3-7483-4017-92f4-0f4f47980d57
relation.isFunderOfPublicationb2658519-a1e4-4d89-8158-1495d2a2ea53
relation.isFunderOfPublication77b2fc20-6311-4e46-98a7-83e46257b93b
relation.isFunderOfPublicationcf779d8b-1517-4249-81b7-65344ce5172d
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PersistentHIVControllersAre_2020.pdf
Size:
494.46 KB
Format:
Adobe Portable Document Format
Description: